This Week Last Year in Medtech: Jan. 8-14
See what Medtronic, Abiomed, and Dexcom were up to this time last year.
Medtronic to Enter Cardiac Mapping Market Via M&A
The acquisition expands Medtronic's portfolio of advanced cardiac ablation products and accessories, including first-time entry into cardiac mapping and navigation systems.
The Reimbursement Tide May Be Turning for iRhythm
Updated rates posted by Medicare Administrative Contractor Novitas may be a positive sign for the company.
Abbott Doesn't Need M&A to Drive Revenue...
Abbott is sitting on a ton of cash. So how will the company prioritize spending in 2022?
Can Non-Invasive Medical Devices Help Halt Liver Disease?
Vibration-controlled transient elastography (VCTE) technology could be used to detect liver disease early and to monitor interventions.
ViCentra Closes Series C Funding to Expand Its Insulin Pump in Europe
The proceeds from the $75 million funding will be used for the European launch of the company’s updated Kaleido insulin patch pump system.
First Biopolymer Heart Valve Implanted in Humans Fares Well in Study
After a successful early feasibility study in the United States, the TRIA biopolymer valve will be studied globally, beginning in India.
Roche Taps Glytec for Digital Health Partnership
The partnership will leverage Glytec's insulin dosing support software to address challenges with hospital inpatient blood sugar management.
Medtronic Set to Fully Launch Micra AV TPS in Japan
The Dublin-based company said the device was the world’s smallest pacemaker and it can now treat patients with AV block.
Abiomed's Successful Early Feasibility Results for preCardia Device
The device is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients.
In a one-on-one interview with MD+DI, Dexcom CEO Kevin Sayer shares the company's biggest lesson from 2021, expectations for G7, his concerns about the supply chain, and more.
About the Author
You May Also Like